clonogenic

clonogenic

 [klo″no-jen´ik]
giving rise to a clone of cells.

clo·no·gen·ic

(klō'nō-jen'ik),
Arising from or consisting of a clone.

clonogenic

/clo·no·gen·ic/ (klo″no-jen´ik) giving rise to a clone of cells.

clo·no·gen·ic

(klō-nō-jen'ik)
Arising from or consisting of a clone.

clonogenic

giving rise to a clone of cells.
Mentioned in ?
References in periodicals archive ?
118 The influence of arsenic trioxide on the clonogenic capacity of bone marrow in patients with newly diagnosed chronic phase chronic myelogenous leukemia (CML) Fri.
clonogenic cultures, PRV-1 determination, and/or bone marrow histology) should be performed in a second step for patients whose serum Epo results are inconclusive.
The mechanisms of lethal damages caused by radiation, both in cancer cells and in normal tissue cells, are by apoptosis or clonogenic cell death (Ross 1999).
Each program, consisting of at least three projects and one or more cores, must address at least two of the six targeted scientific areas: 1) beta cell development, 2) prospective identification and purification of pancreatic stem/progenitor cells, 3) development of clonogenic assays for evaluating potential stem cells, 4) evaluation of pancreatic islets for transplantation, 5) functional imaging of the beta cell, and 6) cell culture modeling of the human pancreatic beta cell.
The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts.
Using in vitro clonogenic assays as a measure of cellular viability (relative to controls) following treatment of five different myeloma cell lines, researchers sought to determine whether QUADRAMET when used in combination with bortezomib would be more toxic to myeloma cells than either agent alone.
Poster Presentation Highlights: -- In vitro clonogenic assays performed using a panel of myeloma cell lines demonstrated synergistic killing following co-treatment with QUADRAMET and bortezomib.
GX15-070 potently inhibited the clonogenic ability of AML blasts at sub-micromolar doses and, in 6/7 primary AML samples, induced apoptosis in CD34+ progenitor cells.
Fas antigen (CD 95) in clonogenic AML and in vitro sensitivity to tipifarnib.
Genasense treatment caused a marked increase in programmed cell death (apoptosis) and a significant reduction in clonogenic survival compared with cells treated with control oligonucleotides.
Xcytrin increased cytotoxic response to bleomycin in clonogenic assays and other lab experiments, and increased tumor response to both agents in animal models.